Direct Answer
Oncology billing is among the most financially complex in all of medicine. The buy-and-bill model for chemotherapy drugs (where the practice purchases the drug and bills the payer at ASP + 6%) creates margin that represents a substantial portion of oncology practice revenue. The administration codes (chemotherapy infusion, injection, and push) layer on top of the drug billing to capture the clinical services surrounding drug delivery. Prior authorization for each chemotherapy regimen, correct J-code unit calculation, and NDC documentation are the critical operational pillars of oncology revenue cycle management.
Table of Contents
Chemotherapy Administration Codes 96401-96549
Chemotherapy administration codes describe how the drug is delivered — not what drug is given: Injection codes (non-infusion): 96401 — chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic; 96402 — hormonal anti-neoplastic; 96405 — intralesional, up to and including 7 lesions; 96406 — more than 7 lesions; Intravenous infusion codes: 96409 — chemotherapy administration, intravenous infusion technique; push technique, single or initial substance/drug; 96411 — push technique, each additional substance/drug (add-on); 96413 — intravenous infusion, up to 1 hour, single or initial substance/drug; 96415 — each additional hour (add-on, up to 8 hours); 96416 — initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump; 96417 — each additional sequential infusion of different drug/substance (up to 1 hour) (add-on); 96422-96423 — intra-arterial chemotherapy; Other routes: 96440 — chemotherapy administration into pleural cavity, requiring and including thoracentesis; 96446 — peritoneal cavity, requiring and including peritoneocentesis; 96450 — into CNS (e.g., intrathecal); Sequential vs. concurrent infusions: sequential infusion: one drug completes, then the next begins; use 96417 (each additional sequential infusion, up to 1 hour) for the second and subsequent drugs; concurrent infusion: two drugs running simultaneously; use 96368 (concurrent infusion, each additional drug/substance) — this is a therapeutic infusion code applied when a concurrent infusion accompanies the primary chemo infusion; Initial service determination: when multiple drugs are given, only one code can be billed as the "initial" service; the initial code is for the drug that takes the most time to infuse (the primary drug); all others are add-ons; Hydration pre-medication: hydration (96360-96361) given to prevent nephrotoxicity (e.g., pre-cisplatin hydration) is separately billable — it is for a clinically independent indication; hydration bundled into the infusion preparation or used for line maintenance is not separately billable.
Antineoplastic Drug J-Codes and Buy-and-Bill
Chemotherapy drugs are billed separately from the administration service using HCPCS J-codes: Common chemotherapy J-codes: carboplatin: J9045 — per 50 mg; cisplatin: J9060 — per 10 mg; paclitaxel: J9265 — per 30 mg; docetaxel: J9171 — per 1 mg; oxaliplatin: J9263 — per 0.5 mg; gemcitabine: J9201 — per 200 mg; doxorubicin: J9000 — per 10 mg; vincristine: J9370 — per 1 mg; cyclophosphamide: J8530 (oral), J9070 (IV, per 100 mg); fluorouracil: J9190 — per 500 mg; bevacizumab (Avastin): J9035 — per 10 mg; trastuzumab (Herceptin): J9355 — per 10 mg; rituximab: J9312 — per 100 mg; Buy-and-bill economics: the practice purchases the chemotherapy drug at its acquisition cost (WAC less any group purchasing organization discounts); the practice bills payers at ASP (Average Sales Price) + 6% for Medicare, or at contracted rates for commercial payers; the spread between acquisition cost and reimbursement is the drug margin; for expensive drugs like bevacizumab ($5,000-$15,000 per infusion), the drug margin can be $500-$2,000 per infusion; Unit calculation: each J-code specifies the unit (per 10 mg, per 50 mg, per 100 mg, per 1 mg); calculate total units based on the prescribed dose; example: carboplatin 450 mg dose = 9 units of J9045 (per 50 mg); NDC documentation: in addition to the J-code, the National Drug Code must be reported on claims for drug products; NDC format: 11-digit number (5-4-2); NDC qualifier: N4; NDC units and unit of measure (ML, UN, GR) must be included; incorrect NDC is a common source of pharmacy claim rejection; Waste and Modifier JW: when a single-dose vial is partially used and the remaining drug is discarded (medically necessary waste): bill the full amount used (in J-code units); on a separate claim line, bill the discarded amount with Modifier JW; Modifier JW preserves reimbursement for the administered portion and documents the wasted drug; Modifier JZ: when there is no drug waste (entire vial administered or all surplus stored and used), append Modifier JZ to indicate zero waste.
Immunotherapy and Targeted Therapy Billing
Immunotherapy and targeted therapies are the fastest-growing segment of oncology drug billing: Checkpoint inhibitors (PD-1/PD-L1/CTLA-4 inhibitors): pembrolizumab (Keytruda): J9271 — per 1 mg; nivolumab (Opdivo): J9299 — per 1 mg; atezolizumab (Tecentriq): J9022 — per 10 mg; durvalumab (Imfinzi): J0179 — per 10 mg; ipilimumab (Yervoy): J9228 — per 1 mg; Administration: all checkpoint inhibitors are IV infusions; bill 96413/96415 (chemo administration codes) even though technically these are immunotherapy agents — the CPT code is based on how the drug is administered (IV infusion), not its pharmacological class; Targeted therapies (oral): many targeted therapies are administered orally (tyrosine kinase inhibitors, CDK4/6 inhibitors); oral chemotherapy HCPCS codes: imatinib (Gleevec): J8521 — per 100 mg; erlotinib (Tarceva): J8565 — per 25 mg; lenalidomide (Revlimid): J8999 or specific code; oral chemotherapy is NOT administered in the office — no administration code is billed; the J-code for the oral drug is billed by the pharmacy dispensing it; Medicare oral chemotherapy parity: MACRA (21st Century Cures Act) provisions aim to equalize coverage of oral vs. IV chemotherapy, but implementation varies by payer; CAR-T cell therapy: chimeric antigen receptor T-cell therapy: Q2042, Q2053, Q2055 (various CAR-T products); these are extremely high-cost therapies ($400,000-$500,000 per infusion) that typically require inpatient administration; prior authorization is universal and extensive; administration uses 96413; Biosimilar oncology drugs: bevacizumab biosimilars, trastuzumab biosimilars, rituximab biosimilars each have distinct Q-codes; the buy-and-bill economics for biosimilars may differ from the reference product — practices should evaluate the spread for each product.
Radiation Oncology Billing
Radiation oncology billing has its own code family distinct from medical oncology: Treatment delivery codes: 77401 — radiation treatment delivery; superficial and/or ortho voltage; 77402 — simple, up to 5 MeV; 77407 — intermediate, up to 5 MeV; 77412 — complex, up to 5 MeV; 77385-77386 — intensity-modulated radiation treatment delivery (IMRT); simple vs. complex; 77373 — stereotactic body radiation therapy (SBRT), treatment delivery, per fraction; Treatment management: 77427 — radiation treatment management, 5 treatments; billed per 5 fractions of treatment delivered; includes weekly review of port films, dosimetry, and physician management; IMRT planning and delivery: 77301 — intensity modulated radiotherapy plan, including dose-volume histograms; 77338 — multi-leaf collimator (MLC) device(s) for IMRT (device); 77385-77386 — IMRT delivery; Stereotactic radiosurgery (SRS): 61796 — stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); cranial; simple (1 target); 61797 — complex (2 or more targets); 77371-77373 for SRS delivery; Simulation and dosimetry: 77280-77295 — simulation codes by complexity; 77300 — basic radiation dosimetry calculation; 77306-77307 — teletherapy isodose plan; 77316-77318 — brachytherapy isodose plan; Brachytherapy: 77750-77799 — brachytherapy codes; 19296-19298 (breast), 55875 (prostate).
Oncology Denials and RCM
Oncology billing denials are high-dollar and concentrated around drug PA and step therapy: Common oncology denial patterns: chemotherapy PA not obtained or expired: every chemotherapy regimen requires PA from commercial payers; PA must specify the drug, the regimen (cycle length and frequency), and the number of cycles approved; regimen changes (dose modifications, drug substitutions) typically require updated PA; NDC error or missing: chemotherapy drug claims without NDC are rejected by many payers; NDC must match the administered product's lot number; unit calculation error: billing incorrect J-code units based on dose is a frequent error; for drugs with small unit denominators (J9171 docetaxel, per 1 mg), a 100 mg dose = 100 units — this is easily miscounted; off-label use without documentation: Medicare and most commercial payers cover chemotherapy only for FDA-approved indications or indications supported by recognized compendia (NCCN, ASCO, etc.); off-label use requires documentation of compendium support; Oncology RCM best practices: PA workflow for every regimen: no chemotherapy should be administered without a confirmed PA on file; PA must include: specific drug(s), regimen, frequency, and number of cycles; when cycles are renewed, the PA must be renewed before treatment continues; compendium documentation: for any drug used for a non-FDA-approved indication, maintain the specific compendia citation (NCCN category, ASCO guideline reference) in the authorization documentation; chemotherapy order verification before billing: a billing workflow that compares the physician's chemotherapy order (drug, dose, route) to the J-code billed and units calculated before claim submission prevents the majority of unit and code errors.
FAQ
What is the correct way to bill when a patient receives both chemotherapy and a supportive care drug (antiemetic or growth factor) in the same infusion visit?
Most oncology infusion visits involve both the primary chemotherapy drug and supportive care medications (antiemetics, corticosteroids, G-CSF, etc.). Billing these correctly requires understanding the hierarchy of administration codes: Step 1 — Identify the primary service: the chemotherapy infusion is always the primary service; bill 96413 for the first hour of chemotherapy infusion; the primary drug is the chemotherapy agent, not the supportive care drug; Step 2 — Bill additional chemo hours: if the chemotherapy infusion exceeds 1 hour, bill 96415 for each additional hour; Step 3 — Bill supportive care drug administration: antiemetics (ondansetron, dexamethasone) given IV: 96374 — therapeutic or prophylactic injection, IV push; or 96365 — therapeutic infusion if infused over more than 15 minutes; G-CSF injections (pegfilgrastim, filgrastim): 96401 — subcutaneous injection; Step 4 — Bill the drugs: bill the J-code for the chemotherapy drug (e.g., J9265 for paclitaxel); bill J-codes for the supportive care drugs: ondansetron J2405; dexamethasone J1100; pegfilgrastim J2505; filgrastim J1442; Hierarchy rule for administration codes: when multiple drugs are given, only one can be the primary administration code (highest level of service); chemotherapy infusion (96413) is always the primary service when chemotherapy is given; a concurrent injection or IV push of a supportive drug is billed as an add-on (96374 or 96368); the primary code is billed once; all subsequent administrations use add-on codes; Documentation required: the infusion flowsheet should document: start and stop times for each drug; route and method of administration; monitoring during infusion; this documentation supports the administration code hierarchy and the separately billed drug J-codes.
How does Medicare's ASP+6% reimbursement for chemotherapy drugs work and what does it mean for practice economics?
Medicare's Average Sales Price (ASP) methodology is the reimbursement mechanism for Part B covered drugs administered in physician offices and hospital outpatient settings: What ASP is: the Average Sales Price is calculated by the drug manufacturer based on all sales of the drug to all purchasers in the US market, weighted by volume sold; ASP is calculated quarterly and published by CMS in its quarterly ASP drug pricing files; Medicare pays ASP + 6% (or the lower of ASP+6% or WAC+3% for certain drugs); the +6% is intended to cover: the cost of administering the drug (storage, handling, mixing); the cost of inventory financing; practice overhead associated with drug management; the spread between the practice's actual acquisition cost and the ASP+6% reimbursement is the practice's margin on the drug; How ASP reimbursement affects practice economics: if a practice's acquisition cost for bevacizumab 400 mg (J9035, 40 units) is $1,800 and ASP+6% for that dose is $2,200, the practice earns approximately $400 per infusion on the drug component alone; this drug margin is a critical revenue stream for oncology practices; practices that use a group purchasing organization (GPO) to purchase drugs at below-WAC prices can increase their spread between acquisition cost and ASP+6% reimbursement; 340B drug discount program: federally qualified health centers, critical access hospitals, and certain other covered entities qualify for 340B pricing, which can provide drugs at substantially discounted acquisition prices; 340B practices bill ASP+6% but acquire drugs at 340B prices, generating a larger spread; controversy: the 340B spread and drug margins more broadly have attracted congressional scrutiny; practices should maintain compliance documentation for all drug billing; Biosimilar drug pricing under ASP: biosimilar drugs have their own ASP calculated separately from the reference product; when biosimilar ASP is lower than the reference product, buying the biosimilar and billing at ASP+6% of its own (lower) ASP may result in a smaller spread than the reference product — practices must calculate both to make informed formulary decisions.
Oncology Revenue Cycle Management Built for Chemotherapy Complexity
Valiant Lifecare's oncology billing specialists manage chemotherapy administration code hierarchy, J-code unit calculation, NDC documentation, prior authorization for every regimen, off-label compendia documentation, ASP+6% buy-and-bill optimization, radiation oncology treatment management codes, and the full spectrum of oncology denial prevention — protecting the drug margin and administration revenue your practice depends on.
Optimize Your Oncology Revenue Cycle